A combination of noninvasive tests can identify patients with metabolic dysfunction–associated steatohepatitis who have stage F2 or F3 pre-cirrhotic fibrosis, potentially easing the need for liver biopsies, according to a new study.
“We just don’t have enough providers to perform liver biopsies on the more 6 million people in this country with [MASH],” Manal Abdelmalek, MD, the director of NAFLD Clinical Research at Mayo Clinic in Rochester, Minn.,